Setmelanotide vs Efinopegdutide
Head-to-head comparison of Setmelanotide (Setmelanotide Acetate) and Efinopegdutide (Efinopegdutide (HM12525A), long-acting glucagon-like peptide-1/glucagon receptor dual agonist) — benefits, dosing, side effects, research data, and where to buy.
Research Score
| Property | Setmelanotide | Efinopegdutide |
|---|---|---|
| Category | Weight Management | Weight Management |
| Full Name | Setmelanotide Acetate | Efinopegdutide (HM12525A), long-acting glucagon-like peptide-1/glucagon receptor dual agonist |
| Molecular Weight | N/A | N/A |
| Half-Life | Approximately 11-16 hours | Approximately 1 week |
| Amino Acids | N/A | N/A |
| Typical Dose | 1-3 mg daily | Trial-dependent; weekly SC dosing |
| Route | Subcutaneous | Subcutaneous |
| Purity | ≥98% | ≥98% |
| Studies Count | 80 | 14 |
| Research Status | Clinical | Clinical |
Setmelanotide Benefits
- ✓reduced hyperphagia
- ✓body-weight reduction
- ✓MC4R pathway activation
- ✓improved satiety signaling
Efinopegdutide Benefits
- ✓reduced body weight
- ✓improved insulin sensitivity
- ✓reduced liver fat
- ✓greater satiety
Setmelanotide Dosing
1 mg SC daily|titrate weekly to 2-3 mg/day|follow study or label-based escalation
Efinopegdutide Dosing
once-weekly subcutaneous injection|dose escalation during lead-in|maintenance dosing in trials
Setmelanotide Side Effects
- ⚠hyperpigmentation
- ⚠nausea
- ⚠injection-site reactions
- ⚠fatigue
Efinopegdutide Side Effects
- ⚠nausea
- ⚠decreased appetite
- ⚠fatigue
Research Overview
Setmelanotide
Setmelanotide has shown clinically meaningful reductions in hunger and weight in POMC, PCSK1, and LEPR-related obesity. It is one of the most important mechanistic peptides for rare-disease obesity research.
Efinopegdutide
Human trials have shown meaningful weight loss and improvements in hepatic steatosis biomarkers. It remains a research compound with ongoing development in metabolic disease.
Ready to buy?
Find both peptides from our verified, lab-tested vendors with purity certificates and third-party testing.